8月10日，福泰制药盘前上涨3.26%，报515.0美元/股，成交额36.79万美元。
消息面上，公司近日发布Q2财报，营收33.3亿美元超市场预期的32.3亿美元，同比增长12.5%；调整后EPS为4.73美元，同比增长4.6%。同时公司上调全年营收指引至131亿-132亿美元，高于此前区间及市场预期的130.6亿美元。
财报发布后，多家机构上调目标价：Cantor Fitzgerald上调至595美元，Rothschild上调至580美元，高盛此前已将目标价调升至652美元。UBS指出公司在管线催化剂方面布局良好，APOL1肾病III期数据有望于明年初读出；RBC认为股价尚未充分反映肾脏项目、povetacicept自免拓展及suzetrigine慢性疼痛等管线潜力。此外，百亿美元收购Crinetics交易预计本季度完成，将新增内分泌业务支柱。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.